evergreen_new_logo.png
Evergreen Therapeutics, Inc. Announces Agreement with ICON plc to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate
June 18, 2021 10:42 ET | Evergreen Therapeutics, Inc.
Bethesda, Maryland , June 18, 2021 (GLOBE NEWSWIRE) -- Evergreen Therapeutics, Inc. (“Evergreen,” or the “Company”), a fast-growing clinical stage company focused on the development of new drugs for...